| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 9,485,000 | 9,617,000 | 8,727,238 | 9,390,388 |
| Cost of goods sold | 2,819,000 | 2,803,000 | 2,519,641 | 4,108,773 |
| Gross profit | 6,666,000 | 6,814,000 | 6,207,597 | 5,281,615 |
| Research and development, net of grant income | 918,000 | 1,262,000 | 1,662,925 | - |
| Selling, general and administrative | 8,610,000 | 9,167,000 | 8,431,880 | 7,002,718 |
| Professional fees | - | - | - | 823,914 |
| Research and development expense | - | - | - | 1,851,230 |
| Total operating expenses | 9,528,000 | 10,429,000 | 10,094,805 | 9,677,862 |
| Loss from operations | -2,862,000 | -3,615,000 | -3,887,208 | -4,396,247 |
| Interest expense, net | -645,000 | -616,000 | -605,134 | -588,153 |
| Gain (loss) on foreign currency transactions | -64,000 | 6,178,000 | 3,013,984 | 2,650,309 |
| Total other income (expense), net | -709,000 | 5,562,000 | 2,408,850 | 2,062,156 |
| Loss before benefit from income taxes | -3,571,000 | - | -1,478,358 | -2,334,091 |
| Benefit from income taxes | -401,000 | - | - | - |
| Net income (loss) available to common stockholders, basic | - | - | - | -2,334,091 |
| Net loss | -3,170,000 | 1,947,000 | -1,478,358 | - |
| Earnings per share, basic | -0.05 | 0.03 | -0.02 | -0.04 |
| Earnings per share, diluted | -0.05 | 0.03 | -0.02 | -0.04 |
| Weighted average number of shares outstanding, basic | 62,753,959 | 62,608,598 | 60,731,929 | 54,453,006 |
| Weighted average number of shares outstanding, diluted | 62,753,959 | 67,166,377 | 60,731,929 | 54,453,006 |
Cytosorbents Corp (CTSO)
Cytosorbents Corp (CTSO)